Arcus Biosciences
RCUS · NYSE · Healthcare · United States
Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:29 PM
Financials at a glance
Source: SEC XBRLAnnual
Quarterly · last 8
Market cap
$3.8B
Day change
+1.3%
Fwd P/E
-9.6
P/B
7.2
Beta
0.80
Revenue (FY2025)
$33.0M
Net margin
-1069.7%
ROE
-55.9%
Revenue CAGR (2y)
-5.6%
EPS (FY2025)
-3.29
Net profit (FY2025)
$-353.0M
Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.
Ask MarketChacha about RCUS
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Financials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $33.0M | $-353.0M | -3.29 | -1069.7% | -55.9% |
| FY2024 | $51.0M | $-283.0M | -3.14 | -554.9% | -58.4% |
| FY2023 | $37.0M | $-307.0M | -4.15 | -829.7% | -66.5% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q1 | $7.0M | $-128.0M | -1.02 | -1828.6% |
| 2025Q3 | $6.0M | $-135.0M | -1.27 | -2250.0% |
| 2025Q2 | $8.0M | $0 | 0.00 | 0.0% |
| 2025Q1 | $8.0M | $-112.0M | -1.14 | -1400.0% |
| 2024Q3 | $7.0M | $-92.0M | -1.00 | -1314.3% |
| 2024Q2 | $11.0M | $-93.0M | -1.02 | -845.5% |
| 2024Q1 | $10.0M | $-4.0M | -0.05 | -40.0% |
| 2023Q3 | $32.0M | $-71.0M | -0.94 | -221.9% |
| 2023Q2 | $29.0M | $-75.0M | -1.04 | -258.6% |
| 2023Q1 | $25.0M | $-80.0M | -1.09 | -320.0% |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC6/12/2026material
- SEC5/5/2026material
- SEC5/5/2026
- SEC4/20/2026material
- SEC3/23/2026material
In the news
- Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?Benzinga · 7/20/2026
- H.C. Wainwright raises Arcus Biosciences stock price target to $45 By Investing.comInvesting.com South Africa · 7/20/2026
- This Insider Has Just Sold Shares In Arcus Biosciencessimplywall.st · 7/15/2026
- Arcus Biosciences President Sells 68,569 Shares in July 2026sekbernews.id · 7/15/2026
- Arcus Biosciences (RCUS) president trades 68,569 shares under 10b5-1 planStock Titan · 7/13/2026
- An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% RunThe Motley Fool · 7/13/2026
- Arcus Biosciences (RCUS) Gains Fresh Attention As Nature Study Puts Valuation Back In Focussimplywall.st · 7/5/2026
- How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Datasimplywall.st · 7/3/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.